Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
about
Biology of adeno-associated viral vectors in the central nervous systemSpecific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseasesFollistatin gene delivery enhances muscle growth and strength in nonhuman primatesThe contribution of mouse models to understanding the pathogenesis of spinal muscular atrophyTelomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancerSwitching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologiesAdvanced Fluorescence Protein-Based Synapse-DetectorsAdeno Associated Viral Vector Delivered RNAi for Gene Therapy of SOD1 Amyotrophic Lateral SclerosisThe Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to BrainRett Syndrome: Crossing the Threshold to Clinical TranslationMECP2 disorders: from the clinic to mice and backState-of-the-art human gene therapy: part I. Gene delivery technologiesPerinatal systemic gene delivery using adeno-associated viral vectorsSpinal muscular atrophy: development and implementation of potential treatmentsCurrent prospects and challenges for epilepsy gene therapyAdeno-associated virus-mediated microRNA delivery and therapeuticsMolecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA)Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan.Induction of Neuron-Specific Degradation of Coenzyme A Models Pantothenate Kinase-Associated Neurodegeneration by Reducing Motor Coordination in MiceLong-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonatesAxonal transport of AAV9 in nonhuman primate brain.Exosome-associated AAV vector as a robust and convenient neuroscience toolCNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model.Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9New tools for investigating astrocyte-to-neuron communication.New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesChanging channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitabilityEarly heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN deliveryReactive astrocytes and therapeutic potential in focal ischemic strokeTranscellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitroPharmacosynthetics: Reimagining the pharmacogenetic approachBAAV transcytosis requires an interaction with beta-1-4 linked- glucosamine and gp96Structure of neurotropic adeno-associated virus AAVrh.8.Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis.Impaired Dendritic Development and Memory in Sorbs2 Knock-Out Mice.Gene delivery to the spinal cord using MRI-guided focused ultrasoundTargeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasoundFocal Delivery of AAV2/1-transgenes Into the Rat Brain by Localized Ultrasound-induced BBB Opening.Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo.
P2860
Q21129328-E31A8504-94D5-4EC7-BB08-5D44C85CA974Q21133553-960FBE8C-CA90-47F5-8B84-C75CD581C1F9Q24598350-95AFE484-93B4-46EB-AC18-63C26565DFDBQ24604444-B0779F6A-BC03-4EF7-9CF8-6BCD60841B9AQ24615809-3AC13BE1-6C88-480F-B27D-E29148DAB743Q24617141-8D4AC0F6-7736-4CB3-B251-4700B02D95FEQ26738370-58C2EA8B-B8FB-485E-B0A8-43F01150684FQ26741129-09B45AE0-8B39-4876-8DDD-B0ACD0C6E2FCQ26745586-EA5C7472-818F-4496-BAB0-045C66057DCCQ26772909-6FC640D4-82A0-49CD-872F-AB10841BECCBQ26799760-FD872B14-2DBB-4803-8F90-995285D00CCCQ26825575-E1089578-D629-4A03-BE3A-4A31932B3C8BQ26852989-CB46AE21-5A84-474B-A869-5BECAC996FEFQ26861377-C61B9601-9BD7-448B-AD9C-E39C212693BCQ27002627-BDF411E5-93DB-4976-8479-A3254E9A5CEDQ27005597-4745C0C1-00A9-40B8-9CB9-EA53C239F6B7Q27007782-B6BFEF41-C59E-4F0A-9E1D-3B8BAD28F004Q27300989-35DE7535-4A8F-418F-8825-E5E3E5911DA6Q27304502-214FA493-130D-48A3-B761-61D68A4FBD28Q27318381-2FEAC5F5-2FE9-4A15-8F37-D7A3D6F5AC14Q27323331-408F7EBB-DB82-4AE7-8F8E-F44AA4913539Q27323458-6E5F08DB-CE05-4CC5-844A-8A8769678D26Q27333793-ACBE4826-7BF5-4DF5-9637-0C1E8C348421Q27342271-3ED42FA2-F9DE-43CC-A880-7B0C5219A116Q27678476-1606D978-17E0-4261-90AD-F9B99DF666B6Q27690725-2E66B078-F8EC-4170-8EAF-E013880D7A94Q28068142-E6CC4EE1-D64D-4553-A103-046AEB516D34Q28081164-BD484E69-29E3-4DC6-94B5-46DE810D8E75Q28288188-857DEDD4-FE94-4E80-A24E-82FDD400779EQ28393830-447BBB23-5F6E-48BA-9C22-B44B59A5A22CQ28484085-FC962B3A-8C48-4F46-A072-19A19E60E537Q28709274-2DAC044D-CF5F-49AA-8FED-259AC5CCFB60Q28748622-1B9CB767-D043-42D9-8A70-93769C8475FBQ30152836-D85ED331-EB73-4774-97ED-234A680BDEA3Q30277241-73A1357F-6CAC-40C5-9637-2DCDC90D66F1Q30376404-2E4E54B0-8E83-4467-B3DA-93B7EAD8517BQ30394722-87BD81E9-6C7A-403D-9D76-6274DECF1746Q30447740-53CDBB36-3843-4A1E-B518-28538FBD8A09Q30457601-54DB8764-BC1C-4DEF-9A14-B9C9B8FC1170Q30474719-A2B3C234-A861-456F-8A08-460A401B150F
P2860
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@en
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@nl
type
label
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@en
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@nl
prefLabel
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@en
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@nl
P2093
P2860
P356
P1433
P1476
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
@en
P2093
Anna Hernandez
Brian K Kaspar
Chrystal L Montgomery
Curtis M Chan
Emily Nurre
Kevin D Foust
P2860
P2888
P356
10.1038/NBT.1515
P577
2008-12-21T00:00:00Z
P5875
P6179
1045285520